Ramdev Released Research Paper On Coronil

New Delhi : Yoga Guru Ramdev, the founder of Patanjali, released the first scientific research paper on the evidence-based medicine for COVID-19 by his organization. Union Health Minister, Dr Harsh Vardhan, and Union Minister Nitin Gadkari were also present at the event.

The medicine for which the data has been released is named Coronil. In June last year, Patanjali claimed that its Ayurvedic medicine can cure coronavirus infection. Following some controversy on the claims, Patanjali’s Coronil Kit was licensed as an ‘immunity booster’.

Swami Ramdev, at the event, said, that people believe that research work can only be conducted in the West. Especially when it comes to Ayurveda, people look at research work with suspicion. He also said that Coronil has benefited lakhs of people during the pandemic.

In June 2020, Patanjali Ayurved had launched ‘Coronil and Swasari’, which the company claimed was the first Ayurvedic cure for COVID-19, the respiratory disease caused by the novel coronavirus or SARS-CoV-2 virus. Launching a kit of three Ayurvedic medicines at Patanjali Yogpeeth in Haridwar, Uttarakhand, Yoga guru Ramdev had said they are proud to announce that the first Ayurvedic, clinically controlled trial based evidence and research-based medicine has been prepared by the combined efforts of Patanjali Research Centre and NIMS.

Ramdev had also said that the medicine could provide ‘100 per cent recovery rate within 3-7 days’.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad